Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Merck
Baxter
McKesson
McKinsey

Last Updated: May 26, 2022

CLINICAL TRIALS PROFILE FOR TECHNETIUM TC 99M SESTAMIBI


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Technetium Tc 99m Sestamibi

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00162045 ↗ A Trial to Determine Radiation Exposure to Organs and Assess the Safety of CARDIOLITE┬« in Pediatric Subjects Completed Lantheus Medical Imaging Phase 1/Phase 2 2005-01-01 The purpose of this Phase I-II multicenter clinical trial is to establish dosimetry and safety profiles for CARDIOLITE┬« (Technetium Tc99m Sestamibi) in pediatric subjects.
NCT00162071 ↗ A Phase II Optimization Study of BMS068645 and Sestamibi Planar Imaging Terminated Forest Laboratories Phase 2 2005-07-01 The primary purpose of this study is to determine the optimal time for myocardial perfusion imaging with Technetium Tc99m Sestamibi following the administration of BMS068645. The safety of BMS068645 will also be studied.
NCT00560495 ↗ Radiation Therapy and Ammonium Tetrathiomolybdate in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer Withdrawn National Cancer Institute (NCI) Phase 1 2007-05-01 RATIONALE: Ammonium tetrathiomolybdate may stop the growth of non-small cell lung cancer by blocking blood flow to the tumor. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving ammonium tetrathiomolybdate together with radiation therapy may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects of giving radiation therapy together with ammonium tetrathiomolybdate in treating patients with stage I, stage II, or stage III non-small cell lung cancer.
NCT00560495 ↗ Radiation Therapy and Ammonium Tetrathiomolybdate in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer Withdrawn Roswell Park Cancer Institute Phase 1 2007-05-01 RATIONALE: Ammonium tetrathiomolybdate may stop the growth of non-small cell lung cancer by blocking blood flow to the tumor. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving ammonium tetrathiomolybdate together with radiation therapy may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects of giving radiation therapy together with ammonium tetrathiomolybdate in treating patients with stage I, stage II, or stage III non-small cell lung cancer.
NCT00767468 ↗ Sorafenib in Treating Patients With Locally Advanced or Metastatic Liver Cancer and Cirrhosis Terminated National Cancer Institute (NCI) Phase 1 2008-10-01 RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of sorafenib in treating patients with locally advanced or metastatic liver cancer and cirrhosis.
NCT00767468 ↗ Sorafenib in Treating Patients With Locally Advanced or Metastatic Liver Cancer and Cirrhosis Terminated UNC Lineberger Comprehensive Cancer Center Phase 1 2008-10-01 RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of sorafenib in treating patients with locally advanced or metastatic liver cancer and cirrhosis.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Technetium Tc 99m Sestamibi

Condition Name

Condition Name for Technetium Tc 99m Sestamibi
Intervention Trials
Progesterone Receptor Negative 1
Breast Cancer 1
Short Bowel Syndrome 1
Cardiovascular Disease 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Technetium Tc 99m Sestamibi
Intervention Trials
Syndrome 2
Liver Neoplasms 1
Neoplasms 1
Cardiovascular Diseases 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Technetium Tc 99m Sestamibi

Trials by Country

Trials by Country for Technetium Tc 99m Sestamibi
Location Trials
United States 13
Taiwan 1
Canada 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Technetium Tc 99m Sestamibi
Location Trials
Minnesota 2
New York 2
North Carolina 1
Wisconsin 1
Washington 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Technetium Tc 99m Sestamibi

Clinical Trial Phase

Clinical Trial Phase for Technetium Tc 99m Sestamibi
Clinical Trial Phase Trials
Phase 4 1
Phase 2 2
Phase 1/Phase 2 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Technetium Tc 99m Sestamibi
Clinical Trial Phase Trials
Completed 3
Terminated 2
Withdrawn 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Technetium Tc 99m Sestamibi

Sponsor Name

Sponsor Name for Technetium Tc 99m Sestamibi
Sponsor Trials
National Cancer Institute (NCI) 3
Mayo Clinic 2
GE Healthcare 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Technetium Tc 99m Sestamibi
Sponsor Trials
NIH 5
Other 5
Industry 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
AstraZeneca
Boehringer Ingelheim
McKinsey
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.